8-K: Azenta Reports Q2 FY26 Results, Lowers Guidance

Azenta, Inc. announced its second quarter fiscal year 2026 results, reporting revenue of $145 million, and revised its full-year guidance downwards due to a cautious demand environment and execution gaps.

Summary

• Azenta reported second quarter fiscal year 2026 revenue of $145 million, a 1% increase year-over-year.
• Organic revenue declined by 3% year-over-year, primarily due to lower revenue in Multiomics and Sample Management Solutions.
• The company announced a significant non-cash goodwill impairment charge of $149 million.
• Diluted EPS from continuing operations was a loss of $3.41, compared to a loss of $0.43 in the prior year quarter.
• Adjusted EBITDA margin for continuing operations decreased by 320 basis points year-over-year to 5.4%.
• The company has revised its full-year fiscal 2026 revenue guidance to be between $603 million and $621 million, down from previous expectations.
• Full-year organic revenue is now expected to range from down 2% to up 1%, a reduction from prior guidance of 3% to 5% growth.
• The long-range plan timeline has been extended by one year to 2029.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative filing due to lowered guidance, execution issues, a significant goodwill impairment, and a delayed divestiture, despite some positive cash flow and liquidity.

Positives

• Revenue from continuing operations increased by 1% year-over-year to $145 million.
• Sample Management Solutions revenue grew 2% year-over-year to $81 million.
• Consumables and Instruments within Sample Management Solutions showed growth.
• The company ended the quarter with $565 million in cash, cash equivalents, restricted cash, and marketable securities.
• Operating cash flow was $12 million, and free cash flow was $5 million for the quarter.
• The company has a $250 million share repurchase program authorized through December 31, 2028, though no repurchases have been made yet.

Negatives

• Second quarter results fell short of expectations due to execution gaps and a cautious demand environment.
• Organic revenue declined 3% year-over-year.
• Multiomics revenue was flat year-over-year, with organic revenue down 2%.
• Sample Management Solutions organic revenue declined 3%, driven by lower revenue in Core Products.
• Operating loss from continuing operations was $165.8 million, a significant increase from the prior year.
• Gross margin decreased by 96 basis points year-over-year.
• Adjusted EBITDA margin decreased by 320 basis points year-over-year to 5.4%.
• Non-GAAP Diluted EPS from continuing operations was a loss of $0.04, compared to $0.01 in the prior year.

Risks

• A more cautious demand environment, particularly in North America.
• Execution gaps within the company's operations.
• The sale of B Medical Systems is uncertain as the buyer has not yet secured financing.
• Potential for further goodwill impairment charges if performance does not improve.
• Supply chain disruptions could impact operations.
• Changes in customer demand and purchasing behavior.
• Macroeconomic, geopolitical, or regulatory developments could negatively affect the business.
• Uncertainty regarding the timing or completion of the B Medical Systems divestiture.

Future Outlook

The company has revised its fiscal year 2026 guidance, now expecting total reported revenue from continuing operations between $603 million and $621 million. Organic revenue is projected to range from down approximately 2% to up 1%, a decrease from previous expectations. Adjusted EBITDA margin is now expected to decline between 125 basis points and flat compared to fiscal 2025. Free cash flow is anticipated to improve 10% to 15% year-over-year. The long-range plan timeline has been extended to 2029.

Management Comments

• "Our second quarter results fell short of our expectations, reflecting both execution gaps and a more cautious demand environment, particularly in North America," said John Marotta, President and CEO of Azenta Life Sciences.
• "As a result, we have revised our fiscal 2026 outlook and taken decisive actions to strengthen execution, reinforce operational discipline, and improve visibility across the business."
• "In 2026, our priority is the transformation of our Multiomics business, with a focus on strengthening commercial execution, optimizing our operating footprint, and improving productivity through Azenta Business System."
• "Given the updated 2026 outlook, we are extending the timeline of our long-range plan targets from 2028 to 2029. This reflects a disciplined and prudent approach to execution in the current environment and, while postponing achievement of the financial targets, does not change our confidence in our strategy."
• "While near-term conditions remain measured, we continue to see a compelling long-term market opportunity and believe the actions underway position Azenta for improved execution, greater consistency, and profitable long-term value creation."

Industry Context

StockSavvy.ai notes that Azenta's revised guidance and focus on operational discipline reflect broader trends in the life sciences tools and services sector, which is experiencing a more cautious demand environment and increased scrutiny on execution and profitability.

Stakeholder Impact

• Shareholders may be negatively impacted by the lowered guidance, reduced profitability expectations, and the significant goodwill impairment charge.
• Employees may face uncertainty due to the focus on operational discipline and potential restructuring within the Multiomics business.
• Creditors may note the company's continued liquidity and cash generation, but the reduced profitability outlook could be a concern.
• Suppliers may be affected by potential changes in demand or operational adjustments.

Next Steps

• Focus on the transformation of the Multiomics business, including strengthening commercial execution and optimizing the operating footprint.
• Implement the Azenta Business System to improve productivity.
• Strengthen leadership and increase operational rigor across the organization.
• Continue to pursue the sale of the B Medical Systems business, subject to buyer financing.
• Execute on the revised fiscal 2026 outlook and long-range plan targets extended to 2029.

Key Dates

Recommendation

While the lowered guidance and significant goodwill impairment are concerning, the company maintains a strong liquidity position, has recurring revenue streams in Sample Management Solutions, and is taking steps to address operational issues. The delayed divestiture adds uncertainty. A 'hold' recommendation reflects the balance of these factors, pending clearer signs of operational improvement and successful execution of the revised strategy.

Keywords

Azenta, SEC Filing, 8-K, Financial Results, Q2 FY26, Revenue Guidance, EBITDA, Goodwill Impairment